Vertex Announces Oral Selective JAK3 Inhibitor VX-509 Shows Statistically Significant Improvement in RA Phase 2b Study
October 18, 2013 at 17:45 PM EDT
Vertex Pharmaceuticals (NASDAQ: VRTX ) today announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once
